Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Blood Cells, Molecules, and Diseases is Scopus-indexed (Q2, CiteScore 3.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Academic Press Inc..
Checked against the index lists dated .
ISSN 1079-9796Verify ISSN ↗1096-0961Verify ISSN ↗
Publisher: Academic Press Inc.
Cost to publish: About US$4,030 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Hematology | 67 / 151 | 55th | Q2 |
| Molecular Biology | 288 / 414 | 30th | Q3 |
| Molecular Medicine | 129 / 179 | 28th | Q3 |
| Cell Biology | 219 / 289 | 24th | Q4 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1995–present, best quartile Q2, CiteScore 3.7.
Blood Cells, Molecules, and Diseases is Q2 in Hematology (rank 67 of 151), Q3 in Molecular Biology (rank 288 of 414) and Q3 in Molecular Medicine (rank 129 of 179), by CiteScore 2025. It is ranked in 4 subject areas in all.
Blood Cells, Molecules, and Diseases is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.7, which places it in quartile Q2 at the 55th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.852, quartile Q2, with an H-index of 105.
The publisher lists an article processing charge of about US$4,030 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Blood Cells, Molecules, and Diseases is published by Academic Press Inc. Its print ISSN is 1079-9796 and its online ISSN is 1096-0961.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Blood Cells, Molecules, and Diseases has an h-index of 114 and a 2-year mean of 1.95 citations per paper (OpenAlex). Its Scopus CiteScore is 3.7, quartile Q2. On 2-year citations it ranks #51 of 148 Scopus journals in Hematology.
Blood Cells, Molecules, and Diseases published 36 papers in 2025; its busiest recent year was 2017 with 111. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2024–2026), authors are most often from United States (21%), India (14.8%) and China (13%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 10 retracted papers are recorded (3.3 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.